Polku Therapeutics Secures $2 Million in Pre-Seed Funding to Advance Groundbreaking Therapies for Neurodegenerative Disorders

Polku Therapeutics Oy, a pioneering biotech firm based in Helsinki, has successfully secured $2 million in funding to propel its mission of revolutionizing treatments for neurodegenerative disorders. Established in 2023, Polku Therapeutics is at the forefront of developing novel disease-modifying therapies aimed at conditions such as Parkinson's disease and Alzheimer’s. What sets Polku apart is its innovative virtual drug development model, which emphasizes cost efficiency and exceptional adaptability. By collaborating with leading international experts and leveraging global resources, the company is uniquely positioned to create impactful healthcare solutions. The newly acquired funding will be instrumental in advancing Polku’s proprietary compounds through critical development milestones, ensuring the delivery of new therapeutic options to patients in need. The funds will support ongoing preclinical studies and facilitate the establishment of strategic partnerships that enhance the drug development pipeline. As neurodegenerative diseases continue to pose significant challenges worldwide, Polku Therapeutics is committed to making a meaningful difference in the lives of patients and their families. With the backing of this latest investment, Polku is poised for accelerated growth and innovation in the field of neurology, reinforcing its dedication to addressing unmet medical needs with cutting-edge therapies. Investors and stakeholders alike are encouraged by Polku’s potential to reshape the landscape of neurodegenerative treatment, and the company remains passionate about its goal of delivering hope and improved quality of life to millions affected by these debilitating disorders.